Lymphomas: Our Clinical Trials

At Memorial Sloan Kettering, you may have access to new treatment options for lymphoma before they are widely available elsewhere. We have extensive experience in reviewing our dozens of active clinical trials and selecting the right option for each person.

The approach to treating lymphomas is changing quickly, as researchers discover more molecular targets that can be treated with drugs. Hundreds of new medicines are in the pipeline, many of which cause fewer side effects than chemotherapy.

For example, with new targeted therapies we’re exploring through clinical trials, we’re now able to select drugs that are specific to the protein changes that make lymphocytes into cancer cells. These therapies may result in fewer side effects than traditional chemotherapy drugs. 

New Chemotherapy Approaches

Our physicians are investigating the effectiveness of various combinations of chemotherapeutic agents and other drugs for non-Hodgkin lymphomas. Although we use a broad array of traditional chemotherapy drugs, new ones are still being discovered. Sometimes they work better or have fewer side effects than current ones.

Pathway-Directed (Biologic) Therapies

Our investigators are testing drugs designed to interrupt or inhibit the molecular processes that tumor cells require to grow and spread. This is one of the most promising areas of research, and is based on understanding the intricate details of what makes a cancer cell a cancer cell. These drugs have the potential to produce far fewer side effects than traditional chemotherapy.

The FDA has just approved some of these drugs for certain types of relapsed or refractory lymphoma. We’re actively studying these and others, learning how to combine them with other drugs and when best to use them.

Immune-System Strategies

MSK’s immunotherapy program tests investigational drugs that encourage the body’s immune system to identify and react against cancer cells. Drugs in this category sometimes help the immune system “see” the cancer cell. Other drugs suppress the cells that normally block the immune system’s response to cancerous changes. Some medicines generally enhance the immune system. 

Tumor-Directed Antibodies

Antibodies are proteins made by B cells that fight infection. Monoclonal antibodies are made in the laboratory to pinpoint a specific target protein on a cancer cell. These are already in clinical use against lymphomas and other diseases.    

The latest research explores how to use antibodies to bring drugs directly to the cancer cell using radioactivity, chemotherapy, or new drugs. One advantage to this approach is that it minimizes exposure to the rest of the body.

Here you can find a continually updated listing of MSK’s current clinical trials for patients with lymphomas and learn more about each study. 

Marginal Zone Lymphoma

Follicular Lymphoma

Untreated (Newly Diagnosed)

A Phase III Study of Rituximab/Lenalidomide or Rituximab/Chemotherapy Followed by Rituximab Maintenance Therapy in Patients with Previously Untreated Follicular Lymphoma
Palomba, M. Lia, MD
[Protocol 12-081]

A Phase II Study of Ibrutinib plus Rituximab in Patients with Previously Untreated Follicular Lymphoma
Palomba, M. Lia, MD
[Protocol 14-018]

Prior Treatment (Relapsed/Refractory)

A Phase I Study of PRT062070 in Patients with Persistent or Recurrent Chronic Lymphocytic Leukemia, Small Cell Lymphocytic Leukemia, or B-Cell Non-Hodgkin Lymphoma
Hamlin, Paul, MD
[Protocol 14-023]

A Phase I Study of CB-839 in Patients with Advanced or Persistent Hematologic Cancers
Younes, Anas, MD
[Protocol 14-053]

A Phase I Study of CPI-0610 in Patients with Progressive Lymphoma
Younes, Anas, MD
[Protocol 13-259]

A Phase IB Study of MK-3475 in Patients with Myelodysplastic Syndromes and Lymphoma
Moskowitz, Craig, MD
[Protocol 13-220]

A Phase Ib Study of Urelumab Given with Rituximab in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Zelenetz, Andrew, MD, PhD
[Protocol 13-252]

A Phase I Study of ABT-199 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma
Gerecitano, John, MD, PhD
[Protocol 11-152]

A Phase I Study of CUDC-907 in Patients with Relapsed or Refractory Lymphoma or Multiple Myeloma
Younes, Anas, MD
[Protocol 13-045]

A Phase IB/IIA Study of ABT-888 in Combination with Bendamustine with or without Rituximab in Patients with Lymphoma, Multiple Myeloma, and Solid Tumors
Gerecitano, John, MD, PhD
[Protocol 10-174]

A Phase I Study of IMGN529 in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Palomba, M. Lia, MD
[Protocol 13-073]

Small Lymphocytic Lymphoma (SLL)

Diffuse Large B-Cell Lymphoma

Untreated (Newly Diagnosed)

A Phase III Study of Ibrutinib (PCI-32765) plus R-CHOP Chemotherapy in Patients Newly Diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL)
Younes, Anas, MD
[Protocol 13-146]

A Phase II Study of Dose-Adjusted EPOCH Chemotherapy with or without Rituximab in Patients with Untreated Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, or Plasmablastic Lymphoma
Noy, Ariela, MD
[Protocol 13-022]

Prior Treatment (Relapsed/Refractory)

A Phase I Study of PRT062070 in Patients with Persistent or Recurrent Chronic Lymphocytic Leukemia, Small Cell Lymphocytic Leukemia, or B-Cell Non-Hodgkin Lymphoma
Hamlin, Paul, MD
[Protocol 14-023]

A Phase I Study of CB-839 in Patients with Advanced or Persistent Hematologic Cancers
Younes, Anas, MD
[Protocol 14-053]

A Phase I Study of CPI-0610 in Patients with Progressive Lymphoma
Younes, Anas, MD
[Protocol 13-259]

A Phase IB Study of MK-3475 in Patients with Myelodysplastic Syndromes and Lymphoma
Moskowitz, Craig, MD
[Protocol 13-220]

A Phase Ib Study of Urelumab Given with Rituximab in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Zelenetz, Andrew, MD, PhD
[Protocol 13-252]

A Phase I Study of ABT-199 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma
Gerecitano, John, MD, PhD
[Protocol 11-152]

A Phase I Study of CUDC-907 in Patients with Relapsed or Refractory Lymphoma or Multiple Myeloma
Younes, Anas, MD
[Protocol 13-045]

A Phase I Study of High-Dose Therapy and Autologous Stem Cell Transplantation Followed by Modified T Cells for Aggressive B-Cell Non-Hodgkin Lymphoma
Sauter, Craig, MD
[Protocol 12-117]

A Phase IB/IIA Study of ABT-888 in Combination with Bendamustine with or without Rituximab in Patients with Lymphoma, Multiple Myeloma, and Solid Tumors
Gerecitano, John, MD, PhD
[Protocol 10-174]

A Phase I Study of IMGN529 in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Palomba, M. Lia, MD
[Protocol 13-073]

Hodgkin Lymphoma

Mantle Cell Lymphoma

Untreated (Newly Diagnosed)

A Phase III Study of Bendamustine and Rituximab with or without Ibrutinib in Older Patients with Newly Diagnosed Mantle Cell Lymphoma
Hamlin, Paul, MD
[Protocol 13-196]

Ofatumumab with or without Bendamustine for Patients with Mantle Cell Lymphoma Who Cannot Have an Autologous Stem Cell Transplant
Hamlin, Paul, MD
[Protocol 11-050]

Prior Treatment (Relapsed/Refractory)

A Phase I Study of PRT062070 in Patients with Persistent or Recurrent Chronic Lymphocytic Leukemia, Small Cell Lymphocytic Leukemia, or B-Cell Non-Hodgkin Lymphoma
Hamlin, Paul, MD
[Protocol 14-023]

A Phase I Study of CB-839 in Patients with Advanced or Persistent Hematologic Cancers
Younes, Anas, MD
[Protocol 14-053]

A Phase I Study of CPI-0610 in Patients with Progressive Lymphoma
Younes, Anas, MD
[Protocol 13-259]

A Phase Ib Study of Urelumab Given with Rituximab in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Zelenetz, Andrew, MD, PhD
[Protocol 13-252]

A Phase IB Study of MK-3475 in Patients with Myelodysplastic Syndromes and Lymphoma
Moskowitz, Craig, MD
[Protocol 13-220]

A Phase I Study of CUDC-907 in Patients with Relapsed or Refractory Lymphoma or Multiple Myeloma
Younes, Anas, MD
[Protocol 13-045]

A Phase I Study of High-Dose Therapy and Autologous Stem Cell Transplantation Followed by Modified T Cells for Aggressive B-Cell Non-Hodgkin Lymphoma
Sauter, Craig, MD
[Protocol 12-117]

A Phase IB/IIA Study of ABT-888 in Combination with Bendamustine with or without Rituximab in Patients with Lymphoma, Multiple Myeloma, and Solid Tumors
Gerecitano, John, MD, PhD
[Protocol 10-174]

A Phase I Study of IMGN529 in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Palomba, M. Lia, MD
[Protocol 13-073]

Burkitt's Lymphoma

T Cell Lymphoma

HIV+ Lymphoma

Waldenstrom's Macroglobulinemia

Adult T Cell Leukemia Lymphoma

Phase I Trials

A Phase I/II Study of IMO-8400 in Patients with Persistent or Recurrent Waldenstrom's Macroglobulinemia
Palomba, M. Lia, MD
[Protocol 14-078]

A Phase I Study of PRT062070 in Patients with Persistent or Recurrent Chronic Lymphocytic Leukemia, Small Cell Lymphocytic Leukemia, or B-Cell Non-Hodgkin Lymphoma
Hamlin, Paul, MD
[Protocol 14-023]

A Phase I Study of CB-839 in Patients with Advanced or Persistent Hematologic Cancers
Younes, Anas, MD
[Protocol 14-053]

A Phase I Study of CPI-0610 in Patients with Progressive Lymphoma
Younes, Anas, MD
[Protocol 13-259]

A Phase Ib Study of Urelumab Given with Rituximab in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Zelenetz, Andrew, MD, PhD
[Protocol 13-252]

A Phase IB Study of MK-3475 in Patients with Myelodysplastic Syndromes and Lymphoma
Moskowitz, Craig, MD
[Protocol 13-220]

A Phase I Study of ABT-199 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma
Gerecitano, John, MD, PhD
[Protocol 11-152]

A Phase I Study of High-Dose Therapy and Autologous Stem Cell Transplantation Followed by Modified T Cells for Aggressive B-Cell Non-Hodgkin Lymphoma
Sauter, Craig, MD
[Protocol 12-117]

A Phase I Study of Brentuximab Vedotin plus Temsirolimus in Relapsed and Refractory Hodgkin Lymphoma
Moskowitz, Alison, MD
[Protocol 13-044]

A Phase I Study of CUDC-907 in Patients with Relapsed or Refractory Lymphoma or Multiple Myeloma
Younes, Anas, MD
[Protocol 13-045]

A Phase I Study of IMGN529 in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Palomba, M. Lia, MD
[Protocol 13-073]

A Phase IB/IIA Study of ABT-888 in Combination with Bendamustine with or without Rituximab in Patients with Lymphoma, Multiple Myeloma, and Solid Tumors
Gerecitano, John, MD, PhD
[Protocol 10-174]